Recent developments include a 1-for-35 reverse stock split in August 2026 to address Nasdaq listing compliance, filing of an S-1 registration statement in June 2026, and quarterly earnings releases and transcripts through early 2026.

• Tenon Medical implemented a 1-for-35 reverse stock split in August 2026 as part of efforts to regain Nasdaq compliance [N1].
• The company filed an S-1 registration statement in June 2026, indicating steps toward regulatory and capital market activities [N2].
• Quarterly earnings transcripts for Q4 2025 and Q3 2025 were published, providing updates on financial results and strategic progress [N5][N6].
• Tenon Medical reported a 37% revenue decline in August 2025, highlighting challenges in sales performance [N7].
• The company’s Q2 2025 earnings transcript was released in August 2025, offering insights into operational results [N8].
• A strategic update on Q3 2024 earnings and progress was published in March 2026 [N4].

Tenon Medical addresses a large and underserved market for SI Joint fusion procedures with innovative, less invasive technologies supported by clinical evidence. The company’s multi-platform product portfolio offers differentiated surgical approaches that may appeal to a broad physician base. Recent acquisitions and capital raises provide resources to support commercialization and clinical studies. The company’s focus on physician training and proprietary surgical protocols may facilitate adoption. The potential market size and low current penetration suggest room for growth in procedure volumes and market share.

Tenon Medical faces significant risks including ongoing operating losses, liquidity constraints, and substantial doubt about its ability to continue as a going concern. The company depends on a limited number of contract manufacturers without long-term supply agreements, exposing it to supply chain disruptions and regulatory compliance risks. The SI Joint fusion market is competitive with established players, and adoption of new technologies may be hindered by procedural complexity and reimbursement challenges. The company’s stock price has not met Nasdaq listing requirements, risking delisting despite recent reverse stock split efforts. Market penetration remains low, and the company’s ability to achieve sustainable profitability is uncertain.

Tenon Medical’s competitive advantage lies in its differentiated portfolio of SI Joint fusion systems offering multiple surgical approaches—The Catamaran System’s inferior-posterior single implant technique and The SImmetry + System’s minimally invasive lateral access approach. Both systems incorporate established orthopedic fusion principles and proprietary instrumentation, supported by clinical evidence including prospective studies demonstrating pain reduction, patient satisfaction, and radiographic confirmation of fusion. This multi-platform strategy enables customization of treatment plans and addresses limitations of existing technologies, such as complexity and morbidity. The company’s focus on physician education, comprehensive training, and proprietary surgical protocols further supports adoption. However, reliance on contract manufacturers without long-term agreements and the relatively early stage of market penetration present challenges to sustaining competitive positioning.

• Liquidity and Going Concern Risk: The company has reported recurring operating losses and negative cash flows, with auditors expressing substantial doubt about its ability to continue as a going concern. Liquidity ratios as of June 30, 2026 indicate constraints, with a current ratio of 0.58 and cash ratio of 0.26 [S2].
• Nasdaq Listing Compliance Risk: Tenon Medical’s common stock has not maintained the minimum $1.00 bid price required for continued Nasdaq listing. The company received a notice in February 2026 and has a compliance period ending August 24, 2026. Failure to regain compliance may result in delisting [S1].
• Supply Chain and Manufacturing Risk: The company relies on a limited number of contract manufacturers without long-term agreements. This exposes Tenon to risks including delays, quality control issues, regulatory non-compliance, and inability to meet demand, which could adversely affect sales and reputation [S1].
• Market Adoption and Competition Risk: The SI Joint fusion market is competitive with established players. Adoption of Tenon’s products may be limited by procedural complexity, reimbursement challenges, and physician acceptance. Low current market penetration indicates adoption hurdles [S1].
• Financial and Capital Raising Risk: Tenon has raised capital through convertible promissory notes and PIPE financing but may require additional funding. Future financing may dilute shareholders or impose restrictive covenants. Availability of capital on acceptable terms is uncertain [S1].

• Tenon Medical, Inc. is a medical device company incorporated in Delaware in 2012, headquartered in Los Gatos, California as of 2026 [S1].
• The company develops and commercializes medical devices for sacro-pelvic disorders, specifically targeting the sacroiliac (SI) joint [S1].
• Tenon offers two main SI Joint fusion systems: The Catamaran System and The SImmetry + System [S1].
• The Catamaran System is a less invasive SI Joint fusion device using a single titanium implant, FDA-cleared in 2018, commercially launched nationally in October 2022 [S1].
• The Catamaran System features a trans-articular, inferior-posterior approach with proprietary instruments and protocols, designed to reduce morbidity and enable radiographic confirmation of fusion [S1].
• The SImmetry + System was acquired in August 2025 and provides a minimally invasive lateral access approach with orthopedic fusion principles, including joint decortication and bone graft placement [S1].
• The company targets three commercial opportunities: primary SI Joint procedures, revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to spine fusion constructs [S1].
• The estimated U.S. market for SI Joint surgical intervention is approximately 270,000 procedures annually, representing a potential $2.1 billion market, with current penetration estimated at 5-7% [S1].
• Tenon’s competitive position is strengthened by offering multiple surgical approaches and systems backed by clinical outcomes including pain reduction, patient satisfaction, and independent confirmation of fusion [S1].
• The company relies on a limited number of contract manufacturers without long-term supply agreements, which poses risks related to supply chain, quality control, and regulatory compliance [S1].
• Tenon’s products are distributed primarily through independent distributors and sales representatives specializing in orthopedics and spine sales, targeting approximately 12,000 physicians [S1].
• The company has incurred operating losses and negative cash flows, with substantial doubt about its ability to continue as a going concern noted by auditors for fiscal year 2025 [S1].
• Tenon raised approximately $4.3 million in March 2026 through senior convertible promissory notes with a maturity date in September 2026, extendable to December 2026 [S1].
• The company completed a PIPE financing in November 2025, raising net proceeds of approximately $2.7 million [S1].
• As of June 30, 2026, Tenon reported cash and equivalents of $1.677 million, current assets of $4.807 million, current liabilities of $8.305 million, and a current ratio of 0.58, indicating liquidity constraints [S2].
• Revenue for the quarter ended June 30, 2026 was $1.279 million, with a net loss of $4.05 million and basic and diluted EPS of -$12.35 per share [S2].
• The company’s common stock has not maintained the minimum $1.00 bid price required for Nasdaq continued listing and was notified of non-compliance in February 2026, with a compliance period ending August 24, 2026 [S1].
• Tenon implemented a 1-for-35 reverse stock split in August 2026 as part of efforts to regain Nasdaq compliance [N1].
• Recent news includes filing an S-1 registration statement in June 2026 and quarterly earnings transcripts and strategic updates through early 2026 [N2][N4][N5].